Advancing Haemophilia Care: An EAHAD Roundtable Discussion - European Medical Journal

Advancing Haemophilia Care: An EAHAD Roundtable Discussion

Hematology

Tune into the latest EMJ Webinar, featuring five key members of the European Association for Haemophilia and Allied Disorders (EAHAD), who join Jonathan Sackier to discuss the EAHAD’s mission, aims, and key projects for the coming year. 

Themes covered include:

  • Gene Therapy Clinical Database
  • Coagulation Factor Variant Database
  • Unique challenges facing women and girls with bleeding disorders
  • The significance of advocacy
  • EAHAD’s mission, current projects, and future goals

 Timestamps:

  • 00:00 – Introduction 
  • 03:38 – EAHAD’s mission  
  • 09:15 – EAHAD’s strategies to ensure high-quality clinical care for patients across Europe 
  • 16:03 – Examples of current EAHAD projects 
  • 18:22 – Gene Therapy Clinical Database 
  • 20:44 – Coagulation Factor Variant Database 
  • 22:58 – Unique challenges facing women and girls with bleeding disorders 
  • 28:37 – The significance of advocacy 
  • 36:04 – EAHAD’s biggest goals for the future 
  • 37:32 – EAHAD Academy platform 
  • 41:13 – The importance of collaboration across disciplines 
  • 45:25 – Final takeaways 

Speakers

Jan Blatný headshot Niamh O'Connell headshot Wolfgang Miesbach headshot Ana boban headshot
Jan Blatný
President, European Association for Haemophilia and Allied Disorders; Associate Professor of Paediatrics, Masaryk University and Children’s University Hospital, Brno, Czechia 
Niamh O’Connell 
Consultant Haematologist, National Coagulation Centre, St James’s Hospital, Ireland 
Wolfgang Miesbach 
Professor of Medicine, Frankfurt University Hospital, Germany 
Ana Boban 
Head of Haemophilia Centre, University Hospital Centre Zagreb, Croatia 
Robert Klamroth headshot
Robert Klamroth
Director of the Comprehensive Care Haemophilia Treatment Center, Vivantes Hospital, Friedrichshain, Germany 

 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.